Nebulized bronchodilator therapy in stable COPD – effect on quality of life and spirometry

S. Santana, E. Norman, P. Watson, S. Gundry, W. Diane, C. Linda, B. Stephen, D. Liam, R. Robert, A. Gbenga (North Shields, United Kingdom)

Source: Annual Congress 2006 - Assessment in COPD patients
Session: Assessment in COPD patients
Session type: E-Posters in free access
Number: 469
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Santana, E. Norman, P. Watson, S. Gundry, W. Diane, C. Linda, B. Stephen, D. Liam, R. Robert, A. Gbenga (North Shields, United Kingdom). Nebulized bronchodilator therapy in stable COPD – effect on quality of life and spirometry. Eur Respir J 2006; 28: Suppl. 50, 469

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease
Source: Eur Respir J 2003 Dec 01;22(6):912-919
Year: 2003



Effects of adding salmeterol to inhaled corticosteroids on lung function and quality of life in patients with mild persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006

The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA)
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012

Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Effect of bronchodilator therapy on the quality of life of pulmonary TB patients
Source: Eur Respir J 2002; 20: Suppl. 38, 442s
Year: 2002

Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study
Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation
Year: 2013


The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 240s
Year: 2002

Changes in the quality of life of pulmonary TB patients depending on the severity of bronchial obstruction when using standard antituberculosis therapy and inhaled bronchodilator therapy
Source: Eur Respir J 2003; 22: Suppl. 45, 21s
Year: 2003

The effect of different bronchodilator drugs on pulmonary function tests, exercise capacity and quality of life in patients with COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 515s
Year: 2005

Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Bronchodilator efficacy of tiotropium in patients with mild COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 616s
Year: 2006

Tiotropium as essential maintenance therapy in COPD
Source: Eur Respir Rev 2006; 15: 51-57
Year: 2006



Lung function and symptom improvement with fluticasone/salmeterol and ipratropium/albuterol in albuterol responsive and non-responsive COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 89s
Year: 2004

Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Efficacy of nebulized arformoterol, a long-acting β2-adrenergic bronchodilator, in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 215s
Year: 2006

Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Effects of supplemental oxygen and high-dose inhaled bronchodilator therapy in exercise performance and dyspnoea in patients with stable COPD
Source: Annual Congress 2004 - Exercise and systemic effects in COPD
Year: 2004


Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009